logo
Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

Yahoo13-03-2025

GAITHERSBURG, Md., March 13, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ('Shuttle Pharma'), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today the closing of its previously announced underwritten public offering of 19,166,667 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.30 per share (the 'Offering'). The aggregate gross proceeds to Shuttle Pharma from the Offering was approximately $5.75 million, before deducting underwriting discounts and commissions and other offering expenses payable by Shuttle Pharma.
Shuttle Pharma intends to use the net proceeds from the Offering to fund Shuttle Pharma's Phase II clinical trial for its lead product candidate, for marketing and advertising services, and for working capital and general corporate purposes.
The Offering was conducted on a firm commitment basis. WestPark Capital, Inc. acted as the Sole Book-Runner in connection with the Offering.
The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-284889), which was declared effective by the Securities and Exchange Commission (the 'SEC') on March 7, 2025. The Offering is being made only by means of a written prospectus that forms a part of the registration statement. A final prospectus relating to the Offering has been filed with the SEC and is available on the SEC's website. Copies of the final prospectus relating to the Offering may be obtained from WestPark Capital, Inc., 1800 Century Park East, Suite 220, Los Angeles, CA 90077, tel: 310-203-2919, e-mail: jstern@wpcapital.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include, but are not limited to, statements concerning the development of our company. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The reader is cautioned not to rely on such forward-looking statements. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including our expectations regarding the success and/or completion of our Phase 2 clinical trials; our success in completing any newly initiated clinical trials, commencing new trials and obtaining regulatory approval following such trials; challenges and uncertainties inherent in product research and development; the uncertainty regarding future commercial success; risks and uncertainties associated with market conditions and the Company's ability to satisfy the closing conditions related to the Offering. These and other factors may cause our actual results to differ materially from any forward-looking statements. Forward-looking statements are only predictions and actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the 'Risk Factors' section of Shuttle Pharma's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025 and Shuttle Pharma's Prospectus filed with the SEC on March 13, 2025, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Shuttle PharmaceuticalsAnatoly Dritschilo, M.D., CEO240-403-4212info@shuttlepharma.com
Investor ContactsLytham Partners, LLCRobert Blum602-889-9700shph@lythampartners.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Luminar Technologies, Inc. (LAZR) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Luminar Technologies, Inc. (LAZR) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Yahoo

time24 minutes ago

  • Yahoo

Luminar Technologies, Inc. (LAZR) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Luminar Technologies, Inc. (LAZR) closed the latest trading day at $3.27, indicating a -5.49% change from the previous session's end. The stock's change was less than the S&P 500's daily loss of 0.27%. Shares of the company witnessed a loss of 23.62% over the previous month, trailing the performance of the Auto-Tires-Trucks sector with its gain of 5.86%, and the S&P 500's gain of 6.9%. Analysts and investors alike will be keeping a close eye on the performance of Luminar Technologies, Inc. in its upcoming earnings disclosure. On that day, Luminar Technologies, Inc. is projected to report earnings of -$1.19 per share, which would represent year-over-year growth of 55.93%. Meanwhile, our latest consensus estimate is calling for revenue of $16.72 million, up 1.64% from the prior-year quarter. For the full year, the Zacks Consensus Estimates are projecting earnings of -$4.29 per share and revenue of $86.64 million, which would represent changes of +53.57% and +14.91%, respectively, from the prior year. Investors should also pay attention to any latest changes in analyst estimates for Luminar Technologies, Inc. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 21.36% higher within the past month. Luminar Technologies, Inc. is currently sporting a Zacks Rank of #2 (Buy). The Automotive - Original Equipment industry is part of the Auto-Tires-Trucks sector. This industry currently has a Zacks Industry Rank of 131, which puts it in the bottom 47% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Luminar Technologies, Inc. (LAZR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

Axcelis Technologies (ACLS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Axcelis Technologies (ACLS) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Yahoo

time24 minutes ago

  • Yahoo

Axcelis Technologies (ACLS) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Axcelis Technologies (ACLS) ended the recent trading session at $67.93, demonstrating a -4% swing from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.27%. Shares of the semiconductor services company have appreciated by 12.57% over the course of the past month, outperforming the Computer and Technology sector's gain of 11.99%, and the S&P 500's gain of 6.9%. The upcoming earnings release of Axcelis Technologies will be of great interest to investors. The company is expected to report EPS of $0.73, down 52.9% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $185.2 million, down 27.8% from the year-ago period. For the full year, the Zacks Consensus Estimates are projecting earnings of $3.29 per share and revenue of $751.1 million, which would represent changes of -46.5% and -26.21%, respectively, from the prior year. It's also important for investors to be aware of any recent modifications to analyst estimates for Axcelis Technologies. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Currently, Axcelis Technologies is carrying a Zacks Rank of #3 (Hold). Looking at valuation, Axcelis Technologies is presently trading at a Forward P/E ratio of 21.51. This represents a discount compared to its industry average Forward P/E of 21.87. It's also important to note that ACLS currently trades at a PEG ratio of 3.92. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Electronics - Manufacturing Machinery industry had an average PEG ratio of 1.78 as trading concluded yesterday. The Electronics - Manufacturing Machinery industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 226, which puts it in the bottom 9% of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow ACLS in the coming trading sessions, be sure to utilize Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axcelis Technologies, Inc. (ACLS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

Halliburton (HAL) Ascends While Market Falls: Some Facts to Note
Halliburton (HAL) Ascends While Market Falls: Some Facts to Note

Yahoo

time24 minutes ago

  • Yahoo

Halliburton (HAL) Ascends While Market Falls: Some Facts to Note

The latest trading session saw Halliburton (HAL) ending at $22.19, denoting a +2.02% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily loss of 0.27%. Prior to today's trading, shares of the provider of drilling services to oil and gas operators had gained 2.06% lagged the Oils-Energy sector's gain of 4.61% and the S&P 500's gain of 6.9%. Investors will be eagerly watching for the performance of Halliburton in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $0.57, reflecting a 28.75% decrease from the same quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $5.46 billion, indicating a 6.42% decline compared to the corresponding quarter of the prior year. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $2.37 per share and a revenue of $21.87 billion, representing changes of -20.74% and -4.7%, respectively, from the prior year. Investors should also take note of any recent adjustments to analyst estimates for Halliburton. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.86% lower. Right now, Halliburton possesses a Zacks Rank of #4 (Sell). From a valuation perspective, Halliburton is currently exchanging hands at a Forward P/E ratio of 9.16. This expresses a discount compared to the average Forward P/E of 15.28 of its industry. Meanwhile, HAL's PEG ratio is currently 3.39. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As of the close of trade yesterday, the Oil and Gas - Field Services industry held an average PEG ratio of 3.54. The Oil and Gas - Field Services industry is part of the Oils-Energy sector. At present, this industry carries a Zacks Industry Rank of 134, placing it within the bottom 46% of over 250 industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Halliburton Company (HAL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store